A Phase IB Trial of Autologous Cytokine‐Induced Killer Cells in Combination with Sintilimab, Monoclonal Antibody Against Programmed Cell Death‐1, plus Chemotherapy in Patients with Advanced Non‐Small‐Cell Lung Cancer

Zhou, Li; Xiong, Yanjuan; Wang, Yang; Meng, Yuan; Zhang, Weihong; Shen, Meng; Zhang, Xinwei; Li, Shuzhan; Ren, Baozhu; Li, Runmei; Han, Ying; Zhang, Jiali; Cao, Shui; Du, Weijiao; Sun, Qian; Wei, Feng; An, Xiumei; Yang, Lili; Zhang, Yuwei; Ma, Wenchao; Xu, Wengui; Zhang, Yi; Jiang, Jingting; Xu, Xiang; Xia, Jianchuan; Liu, Liang; Ren, Xiubao

Published in

Elsevier, Clinical Lung Cancer, 8(23), p. 709-719, 2022

DOI: 10.1016/j.cllc.2022.07.009

Tools

Export citation

Search in Google Scholar

A Phase IB Trial of Autologous Cytokine‐Induced Killer Cells in Combination with Sintilimab, Monoclonal Antibody Against Programmed Cell Death‐1, plus Chemotherapy in Patients with Advanced Non‐Small‐Cell Lung Cancer

Journal article published in 2022 by Li Zhou, Yanjuan Xiong, Yang Wang, Yuan Meng, Weihong Zhang, Meng Shen, Xinwei Zhang, Shuzhan Li, Baozhu Ren, Runmei Li, Ying Han, Jiali Zhang, Shui Cao, Weijiao Du, Qian Sun and other authors.

This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Preprint: archiving allowed

Upload

Postprint: archiving restricted

Upload

Published version: archiving forbidden

Policy details

Data provided by

Published in

Links

Tools

A Phase IB Trial of Autologous Cytokine‐Induced Killer Cells in Combination with Sintilimab, Monoclonal Antibody Against Programmed Cell Death‐1, plus Chemotherapy in Patients with Advanced Non‐Small‐Cell Lung Cancer